Patent ID: 11906532
Assignee: HAEMONETICS CORPORATION
Field: Measurement (Instruments)
Classification: CPC G | IPC G

Claim 1:
2. The method of preparing a formulation according to claim 1, wherein
in step (a),
each member of the series of bovine citrated plasma dilutions has a bovine citrated plasma concentration, the concentration of bovine citrated plasma in any one member of the series of bovine citrated plasma dilutions being different than the concentration of bovine citrated plasma in any other member of the series of bovine citrated plasma dilutions, and
each member of the series of bovine citrated plasma dilutions has a human tissue factor concentration, the human tissue factor concentration of each member of the series of bovine citrated plasma dilutions being the same;

in step (b),
each member of the series of human tissue factor dilutions has a human tissue factor concentration, the concentration of human tissue factor in any one member of the series of human tissue factor dilutions being different than the concentration of human tissue factor in any other member of the series of human tissue factor dilutions,
each member of the series of human tissue factor dilutions has a bovine citrated plasma concentration, the bovine citrated plasma concentration of each member of the series of human tissue factor dilutions being the target bovine citrated plasma concentration, and
each member of the series of human tissue factor dilutions has a heparin concentration, the heparin concentration of each member of the series of human tissue factor dilutions being the same; and

in step (c),
each member of the series of heparin dilutions has a heparin concentration, the concentration of heparin in any one member of the series of heparin dilutions being different than the concentration of heparin in any other member of the series of heparin dilutions,
each member of the series of heparin dilutions has a bovine citrated plasma concentration, the bovine citrated plasma concentration of each member of the series of heparin dilutions being the target bovine citrated plasma concentration, and
each member of the series of heparin dilutions has a human tissue factor concentration, the human tissue factor concentration of each member of the series of heparin dilutions being the target human tissue factor concentration.